Medicon enters agreement with US biotech company Nobex  

The Danish drug development company will test Nobex's drug Apaza at Medicon's Clinical Pharmacology Unit in Copenhagen

The Danish drug development company Medicon has entered an agreement with US biotech company Nobex to test its drug Apaza for the treatment of inflammatory bowel disease (IBD). The study will be performed at Medicon's 20 bed Clinical Pharmacology Unit in Copenhagen. Vice President of Medicon Clinical Pharmacology, Poul Martin Haahr says the company is very proud to have been selected as a Scandinavian collaboration partner for Nobex.


Medicon offers academic and operational services of Phase I-IV tests. The company is based north of Copenhagen and employs 60 people. Nobex is a drug development company specialising in pharmaco-chemistry applied to optimising the delivery of therapeutic drugs. Nobex is based in North Carolina and collaborates with organisations such as Pfizer, Biomedicines, Duke University and the Mayo Clinic. The news is reported by BiotechDenmark online and on Medicon's website.


Link > Medicon 

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×